ACA
TMO icon

Aptus Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Aptus Capital Advisors’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6M Buy
47,091
+851
+2% +$409K 0.16% 114
2026
Q1 		$22.7M Sell
46,240
-11,704
-20% -$6.35M 0.18% 107
2025
Q4 		$33.6M Buy
57,944
+1,757
+3% +$994K 0.24% 82
2025
Q3 		$27.3M Buy
56,187
+44,485
+380% +$20.7M 0.2% 104
2025
Q2 		$4.74M Buy
11,702
+3,031
+35% +$1.27M 0.04% 304
2025
Q1 		$4.31M Sell
8,671
-34,309
-80% -$18.6M 0.04% 300
2024
Q4 		$22.4M Buy
42,980
+5,215
+14% +$2.87M 0.23% 94
2024
Q3 		$23.4M Buy
37,765
+5,996
+19% +$3.55M 0.35% 71
2024
Q2 		$17.6M Buy
31,769
+6,695
+27% +$3.84M 0.31% 75
2024
Q1 		$14.6M Buy
25,074
+2,607
+12% +$1.46M 0.27% 80
2023
Q4 		$11.9M Buy
22,467
+34
+0.2% +$16.5K 0.33% 74
2023
Q3 		$11.4M Sell
22,433
-988
-4% -$526K 0.31% 76
2023
Q2 		$12.2M Sell
23,421
-1,234
-5% -$666K 0.29% 76
2023
Q1 		$14.2M Buy
24,655
+1,709
+7% +$963K 0.38% 53
2022
Q4 		$12.6M Sell
22,946
-1,587
-6% -$841K 0.39% 53
2022
Q3 		$12.4M Buy
24,533
+1,624
+7% +$909K 0.3% 49
2022
Q2 		$12.4M Sell
22,909
-16
-0.1% -$8.81K 0.32% 44
2022
Q1 		$13.5M Buy
22,925
+3,033
+15% +$1.74M 0.34% 36
2021
Q4 		$13.3M Buy
19,892
+3,009
+18% +$1.88M 0.4% 34
2021
Q3 		$9.65M Buy
16,883
+4,049
+32% +$2.22M 0.25% 51
2021
Q2 		$6.47M Buy
12,834
+6,117
+91% +$2.89M 0.19% 64
2021
Q1 		$3.06M Buy
6,717
+155
+2% +$74K 0.11% 99
2020
Q4 		$3.06M Buy
6,562
+948
+17% +$444K 0.14% 95
2020
Q3 		$2.48M Buy
5,614
+48
+0.9% +$19.8K 0.13% 102
2020
Q2 		$2.02M Sell
5,566
-888
-14% -$298K 0.13% 105
2020
Q1 		$1.83M Buy
+6,454
New +$2.04M 0.16% 110

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Aptus Capital Advisors's TMO Position: Q2 2026 in Review

Aptus Capital Advisors increased its Thermo Fisher Scientific (TMO) stake by 1.8% in Q2 2026, buying an estimated $409K and bringing the position to 47,091 shares worth $23.6M. The position accounts for 0.16% of the portfolio, ranked #114.

Aptus Capital Advisors first reported a position in TMO in Q1 2020 and has held it in 26 quarters since. The position peaked at $33.6M in Q4 2025. 2,620 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Aptus Capital Advisors held 47,091 shares of Thermo Fisher Scientific worth $23.6M as of Q2 2026.
  • Aptus Capital Advisors bought 851 Thermo Fisher Scientific shares in Q2 2026, an estimated $409K.
  • Thermo Fisher Scientific made up 0.16% of Aptus Capital Advisors's portfolio in Q2 2026, its #114 holding.
  • Aptus Capital Advisors first reported a position in Thermo Fisher Scientific in Q1 2020 and has held it in 26 quarters since.
  • Aptus Capital Advisors's Thermo Fisher Scientific position peaked at $33.6M in Q4 2025.
  • 2,620 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.